Valued at USD 770 mil, China’s interventional cardiology products market is expected to undergo unprecedented growth due to surging disease incidence according to Clearstate’s market opportunity study

Clearstate analysis of interventional cardiology products’ market opportunity in China reveals a huge market set to experience exceptional growth across several product segments over the next few years. The market is expanding in line with a dramatic rise in cardiovascular disease among increasingly affluent and urbanised Chinese, with the resulting surge in demand for high quality cardiac care. Being the leading cause of death in China, cardiovascular disease has become a major epidemic risk, killing an estimated 2.6 million people annually. Growing at a rapid rate of 25% annually, an estimated 100 million people in China is expected to be diagnosed with cardiovascular disease by the end of 2009.